fish10a ha inviato un aggiornamento 2 mesi fa
Shanghai TheraMabs Bio-technology co., LTD (TheraMabs Bio) was established in 2015 and is located at No. 133, Dongzheng Road, Pudong New Area, Shanghai. It is a leading manufacturing biopharmaceutical company in bio-therapeutics, especially in therapeutic mAbs and fusion protein in China. There are more than 30 biosimilar pipelines which we can provide GMP-compliant APIs (Active Pharmaceutical Ingredients) and Preparations. As an innovation-driven and customer-focused company, TheraMabs Bio provides a broad and integrated portfolio and service to help our customers speed up their drug to market and lower the cost of drug through cost-effective and efficient outsourcing solutions.
TheraMabs Bio whose business covers new drug discovery, process research, quality research, APIs production and formulation filling has more than 200 employees and domestic first-class advanced equipment and has 42000L disposable bioreactor with extensive experience in the production of biological analogues and can produce about 150kg of antibody per year. The annual sales are close to 100 million yuan.
Our biological clinical drug production base in shanghai and Suzhou was based on the United States, the European Union and China GMP requirements to design and build, which can be used to produce monoclonal antibody, fusion protein, cell growth factor and other products. Product sells hot around the world, especially in India, Bangladesh, Pakistan, North America and Europe.
TheraMabs Bio continually seeks ways to support and assist customers in achieving your strategic goals – finding new life-saving and enhancing products and bringing them to market. A hallmark of our services — what remains firm and ingrained in us — is a deep commitment to consistently providing more and better support to our clients worldwide. we hope to cooperate with more customers for mutual development and benefits. We welcome potential buyers to contact us.Nimotuzumab CAS 828933-51-3 biosimilar